When Cannabis Isn’t the Best Medicine: Knowing When to Stop
Cannabis can be a legitimate therapeutic tool, but its medical use requires the same discipline applied to opioids, benzodiazepines, stimulants, and other psychoactive medications. It should be prescribed or recommended for a defined clinical purpose, used at the lowest effective dose, and judged by measurable improvements in symptoms and function. When patients respond by continually increasing their dose without sustained improvement, cannabis may no longer be treatment—it may be becoming part of the problem.
The central clinical principle is straightforward: cannabis should not be escalated indefinitely. A dose increase is justified only when it produces a meaningful, durable improvement that outweighs new risks. If increased exposure produces intoxication, cognitive impairment, anxiety, reduced functioning, or compulsive use without a corresponding improvement in the target symptom, the clinician should stop increasing the dose. In some cases, the appropriate conclusion is not “try more cannabis,” but “cannabis has failed for this patient.”
A Therapeutic Window, Not a Race Upward
For many adults using oral THC-containing products, a practical therapeutic window is approximately 5–20 mg of THC per dose. Individual needs vary to some degree, but doses above 20mg THC should be viewed with caution by the clinician. Further, cannabis-experienced patients may report doses considerably above this range but are not necessarily benefiting from such elevated doses (more on this below). This therapeutic range offers a helpful clinical boundary: beyond it, risk and side effects become increasingly likely, while incremental therapeutic gain becomes less predictable.
The objective of treatment is not a stronger subjective effect. It is improved function. A patient may report that a higher dose “works better” because it creates more sedation, detachment, or intoxication. Yet if that patient is less able to work, drive safely, care for family, exercise, think clearly, or engage in relationships, the treatment is not succeeding. Symptom suppression without functional improvement is often a warning sign of misuse or Cannabis Use Disorder (CUD), particularly when the symptom returns quickly and prompts repeated dosing.
At higher THC doses, particularly outside the therapeutic range, clinicians should expect increasing risk of anxiety, panic, tachycardia, impaired short-term memory, slowed reaction time, dizziness, poor coordination, dysphoria, and next-day cognitive effects. Oral products pose an additional hazard because their effects can be delayed and prolonged.
A clinician should therefore be reluctant to escalate beyond approximately 20 mg of THC per dose unless there is a compelling, documented rationale, careful monitoring, and clear evidence of net benefit. Escalation should never be automatic and development of increasing tolerance should be viewed as a warning sign.
Tolerance Can Become a Clinical Warning
Tolerance is not merely an inconvenience. It can be an early signal that the treatment plan requires reassessment. With high THC exposure, typically outside the therapeutic range, patients experience diminishing effects at the same dose and seek progressively larger amounts to recreate prior experience.
Dose escalation in response to tolerance can create a reinforcing cycle:
- The patient uses cannabis for a symptom such as pain, insomnia, anxiety, or stress.
- The immediate effect feels helpful, but the effect becomes shorter or less complete over time.
- The patient increases dose or frequency.
- Higher exposure causes greater impairment and may worsen sleep quality, anxiety, motivation, or cognitive performance.
- The patient interprets the resulting discomfort as a need for more cannabis.
This is especially concerning when cannabis is being used to manage distress rather than a clearly defined medical condition. Using cannabis reflexively for boredom, loneliness, workplace stress, conflict, grief, or ordinary frustration can shift use from symptom-directed treatment toward self-medication. The distinction matters: medical treatment is intentional, time-limited when appropriate, and monitored against goals. This usually leads to a stable, effective regimen. Self-medication is often reactive, escalating, and detached from an overall care plan.
Dependence and Cannabis Use Disorder
Cannabis can cause dependence. Dependence means the body and brain have adapted to regular exposure; stopping may lead to withdrawal symptoms such as irritability, anxiety, restlessness, insomnia, decreased appetite, vivid dreams, and cravings. These symptoms can be unpleasant enough to drive renewed use even when cannabis is no longer helping the original condition.
Cannabis use disorder is more than frequent use. It involves a pattern of impaired control, continued use despite harm, craving, unsuccessful efforts to reduce use, and increasing priority given to cannabis over work, relationships, health, or other responsibilities. A patient who repeatedly says, “I need more because it is the only thing that helps,” while experiencing worsening functioning, financial strain, family conflict, or adverse effects deserves a careful clinical assessment—not another automatic dose increase.
Dependence and addiction should be discussed without stigma. They are foreseeable risks of a psychoactive medication, especially with high-THC products, frequent dosing, early-age exposure, co-occurring psychiatric illness, or a personal history of substance use disorder. Clinicians should screen before initiating treatment and revisit these questions regularly, particularly when dosing rises or the treatment goal becomes vague.
When to Stop Escalating
Cannabis dosing should stop increasing when one or more of the following occurs:
- The patient has reached roughly 20 mg of THC per oral dose without clear, sustained functional benefit.
- Higher doses improve intoxication or sedation but not the target symptom or daily functioning.
- The patient increasingly uses cannabis outside the agreed indication or schedule.
- Tolerance is driving frequent re-dosing or substantially higher doses.
- The patient develops withdrawal symptoms or significant cravings between doses.
- Cannabis contributes to anxiety, panic, depression, paranoia, impaired cognition, driving risk, or work impairment.
- The patient combines cannabis with alcohol, opioids, benzodiazepines, or other sedating drugs in a way that increases safety risk.
- The original symptom has not been appropriately evaluated, or a more effective evidence-based treatment remains untried.
In these circumstances, a clinician should pause—not merely slow—the escalation. The next intervention may include clarifying the diagnosis, revisiting non-cannabis therapies, reducing THC exposure, tapering frequency, involving behavioral health or addiction medicine, and setting explicit safety boundaries around driving and other hazardous activities.
Patient Who Present with Already High Tolerance
Some patients who come to medical attention having spent years or decades using cannabis for non-medical purposes often have high or extremely high tolerances, and even may have CUD. And yet, they are often coming to medical attention because cannabis is not treating their symptoms. Often the process of reducing their overall dose leads not only to safer use of cannabis but to better symptom control. Such reductions are counterintuitive to cannabis users and therefore effort must be made to develop a long-term rapport with the patient and to discuss use-reduction in non-judgmental terms emphasizing better health, better symptom management, and even reduced cost of medicine as motivators.
When Cannabis Has Failed
A treatment should be called a failure when it does not achieve its agreed therapeutic objective at a safe dose. Failure is not a moral judgment about the patient, nor does it mean cannabis is inherently ineffective. It means that, for this patient, in this circumstance, the expected benefit is insufficient to justify continued exposure.
Cannabis should be discontinued or actively tapered when its harms outweigh its benefits; when escalating doses do not improve function; when use becomes compulsive or difficult to control; or when it delays diagnosis and treatment of the underlying problem. A gradual taper may be preferable for frequent, high-dose users to reduce withdrawal-related insomnia, irritability, and cravings. The taper should be paired with an alternative plan for the symptom that prompted cannabis use in the first place.
The best cannabis treatment plans contain an exit strategy from the beginning. They specify the target condition, expected benefit, dose ceiling, monitoring schedule, and conditions for discontinuation. A patient should know that lack of progress will lead to reassessment—not an endless sequence of higher-dose products.
Cannabis has a place in medicine, but it should not become a substitute for clinical reasoning, mental-health care, rehabilitation, sleep treatment, pain management, or treatment of substance use disorder. When dose escalation becomes the primary strategy, it is time to stop and ask a harder question: is cannabis still helping the patient live better, or is the patient increasingly organizing life around cannabis?